PartnershipApr 29, 2026, 07:35 AM
EBS Secures $50M Multi-Year Manufacturing Deal with SAB BIO
AI Summary
Emergent BioSolutions Inc. announced a multi-year agreement with SAB Biotherapeutics, Inc. to support the process development and manufacturing of SAB-142, SAB BIO's lead program for autoimmune type 1 diabetes. The agreement is valued at approximately $50 million, with $36 million contingent on future regulatory approval and downstream milestones. Emergent's Winnipeg facility will provide end-to-end development and manufacturing services, including process development, scale-up, technology transfer, and clinical and commercial manufacturing.
Key Highlights
- Emergent BioSolutions signed a multi-year agreement with SAB Biotherapeutics.
- The agreement is valued at approximately $50 million.
- $36 million of the agreement value is contingent on future regulatory approval and milestones.
- Emergent will provide end-to-end development and manufacturing services for SAB-142.
- Emergent's Winnipeg, Manitoba facility will be the primary development and manufacturing site.